Retatrutide is an investigational drug with no approved labeling. It has no established side effect profile, because establishing one is part of what the ongoing clinical trials are for.
When you look up side effects for an approved medication, you are reading its FDA-approved labeling: a document built from a completed development program and reviewed by the agency, listing adverse reactions, warnings, and contraindications.
Retatrutide has no such document, because it has not been approved. Adverse events observed during its clinical trials are recorded in the trial data and evaluated by the sponsor, the investigators, and regulators. They are not a finished safety profile, and this site does not present them as one.
Whether retatrutide is safe is an open question. That is what "investigational" means.
Earlier-phase trials enroll comparatively few participants over comparatively short periods. That design can surface common events, but it is not sized to detect uncommon ones, to characterize risks that emerge over longer exposure, or to describe how a drug behaves in people who have other conditions.
This is not a technicality specific to retatrutide. It is the reason the phased trial structure exists: preliminary data cannot be read as a conclusion, and drugs have been withdrawn from development at every stage after later and larger studies changed the picture.
Presenting a preliminary adverse-event list as though it were a safety profile would misrepresent what the underlying data can support.
A Phase 3 program is intended to produce the evidence a regulator needs in order to evaluate questions that earlier studies cannot answer. Those include safety over longer treatment periods, adverse events too uncommon to appear in smaller studies, how a drug behaves in people with conditions such as type 2 diabetes or cardiovascular or liver disease, and effects on organ systems that require sustained observation to assess.
Until those studies are complete and the FDA has reviewed them, statements about how tolerable retatrutide is, how its risks compare with those of other drugs, or how serious its adverse events are, are not supportable. That applies to favorable statements exactly as much as unfavorable ones.
A distinct hazard applies to retatrutide sold online. Because no lawful supply exists, anything sold under that name is unregulated: the identity, purity, potency, and sterility of the contents have not been verified by anyone, and injectable products carry sterility risk in particular.
That means any effects someone experiences from such a product may have nothing to do with retatrutide's own pharmacology. There is no way to know what was in the vial.
If you have used a product like this and feel unwell, contact a healthcare provider and tell them exactly what you took. For severe symptoms — difficulty breathing, chest pain, persistent vomiting, or redness, swelling, or fever suggesting an infection at an injection site — seek emergency care.